Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).
about
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the LiteratureThe role of botulinum toxin A in treating neurogenic bladderTreatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art reviewOveractive bladder syndrome: Current pathophysiological concepts and therapeutic approachesEmerging treatments for overactive bladder: clinical potential of botulinum toxins.A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals.Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review.Botulinum toxin-A for the treatment of overactive bladder: UK contributions.Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis.Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsIntradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study.Management of lower urinary tract dysfunction in patients with neurological disordersDoes Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladderEfficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.The pharmacology of regenerative medicineClinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured BladderIntravesical Botulinum Toxin A Injections for Bladder Pain Syndrome/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled StudiesBotulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelinesBotulinum toxin injection for lower urinary tract dysfunction.Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.OnabotulinumtoxinA in the treatment of neurogenic bladder.Botulinum toxin for conditions of the female pelvis.Botulinum toxin treatment for bladder dysfunction.Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.New therapies in the treatment of overactive bladder.Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice.Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections.Management of refractory OAB in the non-neurogenic patient.Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events.Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.Therapeutic targets for overactive bladder other than smooth muscle.A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders.Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014).
P2860
Q26749613-D5EC13B6-5D1D-4C92-9616-3EE5C603F140Q26767310-AD14601A-422C-4616-B74A-82BDA5A34DA8Q26773579-B2837A1C-DFCD-4FFE-8FB1-CB9AD43BF099Q26851170-0BB01452-0341-4DD4-94C9-37CC16255282Q27022279-9D6737CA-82B2-4FF9-AC4F-18C796CF419DQ33689757-24E4F34E-C8BC-4539-81C0-23874E07E26AQ34195032-A8DA5F9B-DB16-4839-B83F-EDA156E2156BQ34960591-25C1FE8E-5D9C-4AAB-BE3D-B232FF35E6B6Q35741907-4843168D-540C-4165-876C-D0AB32F56F5BQ35839133-A2283D64-B5D6-45EC-9694-A094DAB819D1Q36087246-20FDC979-EAB6-49D6-80CD-CE0B95F28B02Q36115240-B761D26D-AD5D-44CC-9987-3E53CA3DF104Q36284726-FF040BF0-411C-436F-93FC-2FACE4AA4C89Q36401506-A186EC44-4931-4517-B497-2983A5119894Q36573132-F3CDAAB4-61D4-4AE6-A724-E6DCE157E20AQ36589242-E5F8141E-AEA9-4108-A39A-70495876EA68Q36735590-ACF91D9B-8FCD-46B3-B63D-648AFB18A399Q36789948-81DEDE21-F353-4B36-9628-14FD8B1E9E3DQ36974665-5E5F63FF-DAE4-4398-BF09-77797765630BQ37049870-E177DA03-E5A5-4E8D-9F86-0D52F20FB81AQ37275119-94723830-5FFD-459D-B013-285A5AB1D714Q37496473-D73213A7-228A-4171-BB50-BB8D8B373B5DQ37514596-FEB4CE3D-6949-4E5E-BFD8-6169B88DA60FQ37720749-96F695D2-0542-422D-8F98-2BB488048BABQ38008697-07B9289B-913A-4DD3-BCA4-1D44533A8C3FQ38018210-E1460D23-6D7A-4628-9E8D-936D1FD36B67Q38031284-F142890E-01EB-436E-AA0D-A07921B8F2A5Q38043442-F390ACC3-3FCB-4ECA-B565-65EE7F6E5011Q38076295-4592F7D8-1C4F-4161-AC66-E3E1C66CC0C4Q38103282-3C78DC0A-713C-4DDB-BA77-4B09D4C21B2FQ38115204-CECE1C9A-B444-4785-9514-EDBC12C2F547Q38124045-FC425DCC-9352-435F-8534-995ED22FE54EQ38184544-EFAA12C1-9AA3-43DD-BD9A-FBA8974B13A2Q38205871-1F829066-4F52-4315-933A-60B4D14EEF53Q38228516-8A4996C8-C751-4915-9300-D0FD9D87319AQ38248711-0371E101-D243-42DE-AD95-BD663BF53420Q38262923-EEC7C5DA-1C5B-495E-85F2-3739CE1E14D0Q38364035-57AA65B9-4A3F-4635-B637-1CED3B37F373Q38391474-0A69CFEA-8B07-4F5F-AD10-6FA8BF687072Q38406085-9680A89F-11A3-47B5-9B64-3CBB51F225E3
P2860
Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Contemporary management of low ...... dysport (abobotulinumtoxinA).
@ast
Contemporary management of low ...... dysport (abobotulinumtoxinA).
@en
Contemporary management of low ...... : a systematic review of botox
@nl
type
label
Contemporary management of low ...... dysport (abobotulinumtoxinA).
@ast
Contemporary management of low ...... dysport (abobotulinumtoxinA).
@en
Contemporary management of low ...... : a systematic review of botox
@nl
prefLabel
Contemporary management of low ...... dysport (abobotulinumtoxinA).
@ast
Contemporary management of low ...... dysport (abobotulinumtoxinA).
@en
Contemporary management of low ...... : a systematic review of botox
@nl
P2093
P1433
P1476
Contemporary management of low ...... d dysport (abobotulinumtoxinA)
@en
P2093
Altaf Mangera
Antonella Giannantoni
Apostolos Apostolidis
Karl-Erik Andersson
Stavros Gravas
Stephan Madersbacher
P304
P356
10.1016/J.EURURO.2011.07.001
P407
P577
2011-07-13T00:00:00Z